Arvinas, Inc. (NASDAQ: ARVN) is a Healthcare company (Biotechnology) with a market capitalization of $447M. The Maz Rating grades it against the other companies in its sector.
Arvinas, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.82, Arvinas, Inc. trades at 1.6x sales and 0.8x book value. Over the last twelve months it generated about $284M of revenue and a net loss of $10M. It runs a gross margin of 95.9%, an operating margin of -10.7% and a net margin of -3.5%. It shows return on equity of -2.0%, return on invested capital of -5.4% and a free cash flow yield of -36.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 8.39. Over the past 52 weeks the share price ranged from $6.33 to $14.51, with a beta of 1.80.
Arvinas, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 19 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.